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Murine monoclonal antibodies, developed following 
immunization with  human  protein C, were  character- 
ized for  their  ability  to bind antigen  in  the presence of 
either CaClz or excess EDTA. Three  stable clones were 
obtained  which  produced  antibodies that bound to  pro- 
tein C  only  in the presence of EDTA.  All three  antibod- 
ies bound to  the  light  chain of protein  C  on  immunoblots 
and also bound to  the homologous proteins factor X 
and prothrombin in solid-phase radioimmunoassays. 
One antibody,  7D7B10  was  purified  and  studied  fur- 
ther.  The  binding of 7D7B10  to  human  protein  C  was 
characterized  by a KO of 1.4 nM. In competition  studies, 
it  was found that  the  relative  affinity of the  antibody 
for protein C was 20-40-fold higher than for pro- 
thrombin,  fragment 1 of prothrombin, or factor X. In 
contrast,  7D7B10  was  unable  to  bind  to  factor 1X or 
bovine  protein C. The  effect of varying Ca2+ concen- 
tration on the  interaction of the  antibody  with  protein 
C was complex. Low concentrations of Ca2+ enhanced 
the  formation of the  protein C-antibody complex with 
half-maximal  effect occurring  at  approximately 60 PM 
metal ion. However, higher concentrations of Ca2+ 
completely inhibited  7D7B10  binding  to  protein  C  with 
a K o . ~  of 1.1 mM. Furthermore, millimolar  concentra- 
tions of Mn2+, Ba2+, or Mg2+ also completely abolished 
antibody binding to protein C. The location of the 
epitope  was  delineated by immunoblotting and peptide 
studies  and found to be present  in  the  NHz-terminal 15 
residues of protein C. Although  residues  corresponding 
to positions 10-13 of human  protein  C  were necessary 
for maximal binding of the  antibody,  they  were  not 
sufficient. No evidence could be found for involvement 
of the epitope  in  metal  binding per se. Therefore,  the 
effect of Ca2+ on antibody  binding is thought  to  be  due 
to metal-dependent  conformational  changes in  protein 
C. It seems  likely that Ca2+  occupation of a high  affinity 
site, shown by others  to be  located  in the  epidermal 
growth factor-like domain, causes a conformational 
change  in  the  NHz-terminal region of protein  C  which 
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is favorable for antibody interaction, whereas Ca2+ 
binding  to  the low affinity site($, known  to  be  present 
in  the y-carboxyglutamic  acid  domain,  causes an un- 
favorable  conformational  change. 
Protein C is a vitamin K-dependent plasma protein that 
plays an important role in hemostasis. This protein shares 
extensive homology with regions of other vitamin K-depend- 
ent proteins at  both  the primary structure  and gene levels 
(Fernlund and Stenflo, 1982; Stenflo and Fernlund, 1982; 
Foster and Davie, 1984; Long et aL, 1984; Foster et al., 1985; 
Plutzky et al., 1986). However, protein C functions as an 
anticoagulant (Kisiel et al., 1977; Walker et al., 1979; Suzuki 
et al., 1983; Vehar and Davie, 1980) and has been reported to 
enhance fibrinolytic activity (Comp and Esmon, 1981; van 
Hinsbergh et al., 1985). The  NHz-terminal approximately 40 
residues of human protein C contain 9 y-carboxyglutamic 
acid (Gla)’ residues, and  are referred to  as  the “Gla domain.” 
This region binds Ca2’, resulting  in  a conformational change, 
and is important for the interaction of the molecule with 
phospholipid. The Gla domain is  followed  by two cystine-rich 
epidermal growth factor (EGF) homology domains that con- 
tain a single residue of P-hydroxyaspartic acid (Drakenberg 
et al., 1983). This EGF-like region has been shown to contain 
a single high affinity binding site for Ca2+, occupation of 
which also results  in  conformational changes in the molecule 
(Esmon et al., 1983; Johnson et al., 1983; Ohlin and Stenflo, 
1987; Ohlin et al., 1988). 
The heavy chain of protein  C is the serine  protease homol- 
ogy domain, and cleavage of an Arg-Leu bond near the amino 
terminus of the heavy chain results in conversion of the 
zymogen protein  C to  the enzyme-activated protein  C (Kisiel, 
1979). The activation reaction is dramatically affected by 
Ca2+ binding  to the high affinity site in the  EGF homology 
domain,  although  inhibitory or acceleratory effects are seen, 
depending upon the activating enzyme used (Esmon et al., 
1983; Johnson et al., 1983; Kisiel et al., 1987a; Orthner et al., 
1988). 
Several investigators have reported monoclonal antibodies 
The abbreviations used are: Gla, y-carboxyglutamic acid; APC, 
activated protein C; BSA, bovine serum albumin; EGF, epidermal 
growth factor;  ELISA,  enzyme-linked  immunoadsorbent assay; PCA, 
protein C activator from A. contortrix contortriz; PBS, phosphate- 
buffered saline; RIA, radioimmunoassay; SDS, sodium dodecyl sul- 
fate; PAGE, polyacrylamide gel electrophoresis; TLCK,  l-chloro-3- 
tosylamido-7-amino-2-heptanone; TBS, Tris-buffered  saline, pH 7.5; 
HPLC, high pressure liquid chromatography. 
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to protein C which bind to the protein only in the presence 
of metal  ions  (Wakabayashi et al., 1986; Ohlin and Stenflo, 
1987; Mimuro et al., 1987; Nakamura and Sakata, 1987; 
Stearns et al., 1988). These antibodies are thought to be 
conformation-specific ligands that bind to epitopes present 
only in metal-stabilized conformers of protein C. More re- 
cently, a monoclonal  antibody to protein C has been described 
which  only  binds to this molecule in the absence of divalent 
metal  ions  (Church et al., 1988). In this report,  we  describe 
the production and characterization of a unique  monoclonal 
antibody to human protein C whose interaction with the 
molecule is enhanced  by  divalent  metal ions in the micromolar 
concentration range  but inhibited by  divalent metal ions in 
the millimolar  concentration  range. 
EXPERIMENTAL  PROCEDURES 
Materials 
The chromatographic media DEAE-Sephadex A-50, DEAE-Sepha- 
cel, and Sephadex G-100 were from Pharmacia  LKB Biotechnology 
Inc. Affi-Gel  10 and Chelex  100  were  from Bio-Rad. Substrates and 
inhibitors were purchased as follows: H-D-Val-Leu-Arg-p-nitroani- 
lide-2HC1 (S-2266) was from Helena Laboratories, o-phenylenedi- 
amine was  from Abbott Laboratories, TLCK was from Calbiochem. 
Proteins and immunological reagents were obtained as follows: a- 
chymotrypsin, from bovine pancreas, type 1-s, was from Sigma; 
prothrombin complex concentrate  (Proplex) was obtained from Hy- 
land Division, Baxter Healthcare; Assera protein C, a specific rabbit 
anti-human protein C, was purchased from American Bioproducts; 
peroxidase-conjugated goat anti-mouse immunoglobulin, affinity pu- 
rified, was  from Cappel Laboratories; sheep anti-mouse immunoglob- 
ulin, affinity purified, 1251-labeled F(ab'),, 100 pCi/ml, 17 pCi/pg 
protein was  from Amersham; mouse immunoglobulin typing kit was 
from Boehringer Mannheim; specific rabbit anti-human prothrombin 
was purchased from Calbiochem. 
Monoclonal  Antibody  Production 
Male  BALB/c  mice  were immunized with three consecutive injec- 
tions of purified human protein C. The immunization schedule and 
fusion protocol were carried out  as described previously (Strickland 
et al., 1988) except that the P3-NSlAg 4.1 myeloma cell line was 
utilized. Cell supernatants were assayed using a solid-phase RIA in 
which wells were coated with 100 ng of human protein C. Each 
supernatant was incubated in a buffer containing either 10 mM Ca2+ 
or 10 mM EDTA. Binding of the antibody to  the wells was detected 
hy adding a dilution (1/1,000) of rabbit anti-mouse IgG followed by 
Iz5I-labeled protein A (20,000 cpm/well). Preparation of the ascites 
fluid and purification of the IgG fraction were carried out  as described 
previously (Strickland et al., 1988). IgG subtyping was performed by 
ELISA using  mouse immunoglobulin typing reagents from Boehrin- 
ger Mannheim according to  the manufacturer's instructions. 
Cell-sorting  Analysis 
The 7D7B10 hybridoma, cultured in flasks using serum-supple- 
mented basal media, was subjected to flow cytometric analysis (Bio- 
Response). The results showed a monomodal distribution of immu- 
noglobulin expression, indicating a homogeneous population of cells. 
Protein  Purification 
The following vitamin K-dependent proteins were purified from 
cryoprecipitate-poor human plasma. Proteins  C and S were isolated 
by barium citrate precipitation and elution, ammonium sulfate frac- 
tionation, and DEAE-Sephadex A-50 chromatography (Thompson, 
1977) followed by dextran sulfate chromatography (Kisiel, 1979). 
Activated protein C was prepared by treatment of protein  C with 
0.1% protein C activator (w/w) purified from the venom of Agkistro- 
don contortrin contortrix (Orthner et al., 1988). Prothrombin and 
factor X were purified from prothrombin and factor X-enriched pools 
resulting from the large scale production of factor IX concentrate 
(Menache et al., 1984) by rechromatography on sulfated dextran 
(Miletich et al., 1980)  followed  by chromatography on Sephadex G- 
100. a-Thrombin was purified as described previously (Orthner and 
Kosow, 1980). Fragment 1 of prothrombin was isolated as a by- 
product of the thrombin preparation (Aronson et al., 1980). Factor 
I x  was purified from Proplex using the monoclonal antibody 1H5B7 
coupled to Affi-Gel 10 by adsorption in the presence of 25 mM MgC12 
and elution with 10 mM EDTA (Wang et al., 1987). Bovine protein C 
was purchased from Enzyme Research Laboratories. The identity 
and integrity of the bovine protein were confirmed by SDS-PAGE, 
activity measurements, and by NH2-terminal sequence analysis. All 
proteins were greater than 95% homogenous as judged by SDS-PAGE. 
Protein  concentrations were determined spectrophotometrically 
byusing the following molecular weights and absorption coefficients: 
protein C, M,  62,000, E;% = 14.5 (Kisiel, 1979); protein S, M,  70,000, 
E;Z = 9.5 (DiScipio and Davie, 1979); prothrombin, M,  72,000, E;% 
= 13.8 (Kisiel and  Hanahan, 1973); factor X, M,  59,000, Eig = 11.6 
(DiScipio et al., 1977); factor IX, M, 57,000, E;,$, = 13.2 (DiScipio et 
al., 1977); a-thrombin, M,  36,500, E;Z = 18.3 (Fenton et al., 1977); 
fragment 1 of prothrombin, M,  30,000, E% = 11.0 (Prendergast and 
Mann, 1977); mouse  IgG, M ,  150,000, E$& = 15.5, 
Proteolytic  Digests 
a-Chymotrypsin was treated with TLCK to inactivate  any  poten- 
tial contaminating trypsin by incubating 2 mg/ml a-chymotrypsin 
with 1 mM TLCK  in TBS  at 37  'C for 3.5  h. Prothrombin digestions 
were performed by incubating 1.2 mg/ml prothrombin with 1.0 pg/ml 
TLCK-treated chymotrypsin in 0.05 M Tris-HC1, 0.05 M NaC1, 5.5 
mM EDTA, pH 7.5, at 37 "C for 2 h. Prothrombin was digested with 
a-thrombin under identical conditions but using 2.0 Fg/ml a-throm- 
bin. Digestion of protein C was done by incubating 0.73  mg/ml protein 
C with 1.0 pg/ml TLCK-treated chymotrypsin in 0.05 M Tris-HC1, 
0.03 M NaCl, pH 7.5, containing either 5.5 mM EDTA or 5.0 mM 
CaClz at 30 "C. 
Decarboxylation of Gla 
The Gla residues in prothrombin were decarboxylated according 
to  the method of Bajaj et al. (1982) by heating (110 "C, 15 h) prothrom- 
bin that had been lyophilized from 0.1 M NH4HC03, pH 8.0. The Gla 
content of heat-decarboxylated and control prothrombin was deter- 
mined by NH2-terminal sequence analysis. The decarboxylation pro- 
cedure resulted in the quantitative conversion of Gla to glutamic acid 
residues based upon the fact that  the observed repetitive yields for 
glutamic acid were in excess of 90% at all expected positions, with 
the exception of residue 19 (85% repetitive yield). The functional 
activity of heat-decarboxylated prothrombin was examined in  initial 
rate studies of its activation by factor Xa in the presence of phospho- 
lipid and varying concentrations of Ca2+ as described previously 
(Kosow and Orthner, 1979). The  rate of activation of heat-decarbox- 
ylated prothrombin was insensitive to Ca2+, in contrast to control 
prothrombin (treated identically with the exception of heating) and 
the initial prothrombin (no treatment) whose rates of activation were 
enhanced similarly at increasing Ca2+ concentrations. 
SDS-PAGE and  Immunoblotting 
Proteins were separated on slab gels (14 X 10 X 0.15 cm) consisting 
of a 10% resolving  gel and a 4% stacking gel using the buffer system 
of Laemmli (1970). Gels  were either  stained with Coomassie Blue R- 
250 or transferred electrophoretically to nitrocellulose (Schleicher & 
Schuell, ME 24, 0.2 pm)  in  a  Trans-Blot  apparatus (Bio-Rad) at 30 
V for 18 h with cooling using 25 mM Tris, 190 mM glycine, 20% 
methanol buffer (Towbin et al., 1979). The blot was blocked with 
PBS containing 5% (w/v) nonfat dry milk (PBS/milk) for 2 h. It was 
then incubated with 10 pg/ml mouse IgG for  2 h, rinsed three  times 
for 10 min each, and incubated with a 1/1000 dilution of sheep anti- 
mouse immunoglobulin, 1251-labeled F(ab')z,  and again rinsed three 
times, 15 min each. All incubations and rinses were performed at 
25 "C utilizing PBS/milk. After drying, the immunoblot was inserted 
into an X-Omatic Cassette (Eastman Kodak) containing a single 
Cronex Lightning Plus intensifying screen (Du Pont) and Kodak 
XRP film and exposed at -70 "C. 
ELISA 
The  data presented in Figs. 2, 4, 5, 8 and Table I11 were derived 
from a sandwich ELISA. In this assay, wells of microtiter plates 
(Immulon 11, Dynatech Laboratories) were coated with 100 pl of 
specific rabbit  anti-human  protein C diluted 1/100 in 0.1 M sodium 
bicarbonate, pH 9.6, for 1 h at 37 "C and blocked with TBS, 0.1% 
BSA for 1 h at 25 "C. Following washing, mixtures containing the 
monoclonal antibody 7D7B10 at  final  concentrations of  20, 10,  or 5 
pg/ml and varying concentrations of protein  C  in 0.05 M Tris-HC1, 
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pH 7.3,  0.1% BSA, 30 mM EDTA or varying concentrations of 
different  divalent  metal  ions as indicated in  the figure legends were 
added to  the coated wells and incubated for 1 h a t  25 “C with shaking 
at  1000 rpm. The wells were then aspirated and washed, and the 
amount of 7D7B10 present was detected  with peroxidase-conjugated 
goat anti-mouse immunoglobulin. In a variation of the sandwich 
assay, protein C was incubated with 7D7B10 in the absence or 
presence of increasing concentrations of one of the homologous 
vitamin K-dependent proteins (see Fig. 5) or various peptides (see 
Fig. 8 and  Table 111). The  protein C-7D7B10 complex was captured 
and quantitated as before. The data obtained for the binding of 
protein  C to 7D7B10 (see Fig. 2) were fit  to  the following equation 
(Ingham et al., 1988): 
M = M,., {[protein C]/& + [protein C]} 
where M represents the  percent of maximal  binding  (measured by 
percent change in absorbance), M,., represents  the maximal  binding 
(measured by maximum change in absorbance). [protein C] repre- 
sents the concentration of protein C, and KD is the dissociation 
constant.  Fitting was accomplished using  nonlinear regression analy- 
sis, and once the fit was obtained, the best fit curve and  data were 
plotted in the form of a semi-log plot. 
Sequence Analysis and Peptide  Synthesis 
NH2-terminal sequence analysis was performed by automated  Ed- 
man  degradation  on  a  Beckman  system 890M series  Sequencer  using 
a 0.1 M Quadrol program. The phenylthiohydantoin  derivatives were 
analyzed by HPLC  on  an ODS Zorbax (C18) column. Peptides were 
synthesized by the Fmoc-polyamide method of solid-phase synthesis 
using  a Milligen 9050 Pepsynthesizer. Purity was assessed by HPLC 
on a Waters Maxima 820 system using a pBondapak Cls column. 
Amino acid analyses were performed using  a Pic0 Tag work station. 
The  amino acid content of all  peptides was in agreement  with the 
intended sequence. 
Functional Assays 
The effects of the monoclonal antibody  on the functional  properties 
of protein  C or APC were evaluated as follows. 
Protein C Actiuation Assay-Protein C, 0.2 pM, was incubated in 
0.05 M Tris-HC1, 1 mg/ml polyethylene glycol 8000, pH 7.5, contain- 
ing 5 mM EDTA in  the absence or presence of a 10-fold molar excess 
of antibody for 20 min. PCA was added to a  final concentration of 10 
nM to  start  the reaction. At exactly 1 and 5 min later,  the reaction 
was stopped by the addition of soybean trypsin  inhibitor  to 0.8 mg/ 
ml, and APC was measured following the addition of NaCl to 0.2 M 
and  the chromogenic substrate S-2266 to 0.9  mM. 
APC Amidolytic  Actiuity-APC (64 nM) was preincubated in  the 
absence or presence of an 8.6-fold molar excess of monoclonal anti- 
body in 0.05 M Tris-C1, 0.15 M NaCl, 1 mg/ml polyethylene glycol 
8000, pH 7.5, with 5.0 mM EDTA for 15-30 min in AquaSiP-treated 
cuvettes. The reaction was started by the addition of S-2266 substrate 
to a final concentration of  0.4  mM, and  p-nitroaniline formation was 
measured continuously at  410 nm  on  a Cary 219 spectrophotometer. 
Progress curves were linear, and initial velocities were determined. 
Inactivation of Factor VII Cofactor Actiuity-Highly purified factor 
VI11 prepared by immunoaffinity  chromatography  (AHF-M,  Hyland 
Division, Baxter Healthcare) was equilibrated in 0.05 M Tris-HC1, 
0.1 M NaC1, pH 7.5, containing 0.5 mM CaC12 and 0.01% (v/v) Triton 
X-100 by  gel filtration.  APC  (92 nM) was preincubated in  the absence 
or presence of a 16.5-fold molar excess of monoclonal antibody in 
equilibration buffer containing 0.5 mM CaC12 and 0.01% Triton  X- 
100 (see above) in a total volume of 100 pl. After 20 min, 100 pl of 
factor VI11 was added to a  final concentration of 6.0 IU/ml to  start 
the reaction. This  concentration of  CaC12 was sufficient to stabilize 
factor VIII, while not being high enough to inhibit the binding of 
antibody to APC. At varying times, aliquots (10 pl) were removed 
and assayed for the ability of factor VI11 to accelerate factor IXa- 
catalyzed activation of factor  X  (factor VI11 cofactor  activity)  using 
protein, phospholipid, and  substrate reagents  supplied in the  Coatest 
factor VI11 kit (Helena  Laboratories). 
RESULTS 
Preparation  and  Partial Characterization of Monoclonal An- 
tibodies-Hybridomas were prepared by fusing spleen cells 
derived  from  BALB/c mice immunized with  protein C with 
the  P3-NSlAg 4.1 myeloma cell line. Since  the goal of the 
present  study was to  obtain monoclonal antibodies sensitive 
to metal ion-induced conformational states of protein C, 
hybridoma supernatants were screened using a solid-phase 
RIA in  the  presence of either 10 mM Ca2+ or  EDTA.  Hybri- 
domas  producing  several  different  types of monoclonals were 
identified. Representative  screening  results  are  demonstrated 
in Fig. 1. The  majority of the  antibodies  bound  to  protein C 
regardless of the  metal  ion  content. A few antibodies required 
the  presence of Ca2+  for binding (e.g. well 2A),  and  surpris- 
ingly, several antibodies  bound  to immobilized protein C  only 
in  the  presence of EDTA,  with  no  binding  detected  in  the 
presence of Ca2+ (e.g.  wells 2E, 2G, F9, and FIO). To illustrate 
the  relative frequency of these  types of antibodies,  the  num- 
bers of wells containing cells  from  two separate  fusions  that 
produced antibodies  to  protein C are  summarized in Table I. 
The frequency of “EDTA-dependent’’ antibodies, measured 
from  initial  screening  results, was 2.5-fold higher than  that of 
the  “Ca2+-dependent”  antibodies. 
Three of the clones producing  EDTA-dependent  antibodies 
were examined  in more  detail. The specificity of these  anti- 
bodies  was examined by  a solid-phase RIA in which microtiter 
wells were coated  with  either  factors  IX, X, 11, or  protein S. 
All of these  proteins were purified to homogeneity and were 
depleted of potential trace contamination by protein C by 
immunoaffinity  chromatography  prior  to use. The  results of 
these studies are summarized in Table 11. All three clones 
showed  cross-reactivity with  prothrombin  and  factor X but 
not  to  any of the  other  proteins  tested.  The ybridoma super- 
natants were also  characterized  as  to immunoglobulin  class 
and  subtype by ELISA  using specific antisera,  and all three 
EDTA 
FIG. 1. RIA screening of hybridoma  supernatants  for metal 
dependence. Microtiter wells were coated with protein  C (100 ng/ 
well) and incubated  with 50-pl cell supernatants. Antibody binding 
was detected as described under  “Experimental Procedures.” Dupli- 
cate plates were assayed in the presence of either  10 mM Ca2’ or 10 
mM EDTA. 
TABLE I 
Frequency of antibody types identified in initial screening assay 
Antibodv t w e  No. of positives Percent 
Metal-independent 133 86 
EDTA-dependent  15  10 
Ca2+-dependent - 6  4 
Total 154 100 
- 
TABLE I1 
Screening of hybridoma supernatants by solid phase RIA 
Binding to homologous proteins” 
Clone EDTA present CaZ+ present subtype 
PC x I1 s IX PC x I1 s IX 
Ig 
Assays were performed in the presence of 10 mM CaC12 or 10 mM 
EDTA.  PC,  protein C; X, 11, IX, factors; S, protein S. 
clones  produced  immunoglobulins that were of the IgGl sub- 
type with K light  chains.  Since all three of these  antibodies 
had similar  specificities in solid-phase  RIA and  appeared  to 
bind  to  the  light  chain of protein C  when  assessed by Western 
blotting,  one (7D7B10) was chosen for further  characteriza- 
tion. The hybridoma was expanded in mice, and IgG was 
purified to homogeneity from  the  ascitic fluid. 
Specificity of 7D7BlO”The specificity of this  antibody was 
examined by immobilizing the  antibody  on Affi-Gel 10 (2 mg 
of IgG/ml of gel). Either  citrated  plasma  or  factor  IX complex 
(Hyland  Therapeutics) dialyzed previously against TBS con- 
taining  10 mM EDTA was  applied to  the column equilibrated 
in this same buffer. After washing, the bound protein was 
eluted with TBS  containing  10 mM CaC12. Protein C activity 
coeluted with the absorbance at 280 nm. Analysis of the 
material by SDS-PAGE, Western blotting, and functional 
assays revealed that  the major component was protein C  with 
significant amounts of prothrombin.  Since  these  starting  ma- 
terials  contained considerably more  prothrombin  than  protein 
C, these  studies reveal that 7D7B10 has a much higher affinity 
for protein C than for prothrombin. In other experiments 
using purified proteins,  it was found  that  the  immunoadsor- 
bent also bound  APC  as well as  fragment 1 of prothrombin, 
both of which were eluted  with a  buffer containing CaC12. 
The affinity of this monoclonal antibody for protein C  was 
measured in a  sandwich ELISA. Fig. 2  shows the  results of 
an  experiment  in which a constant  amount of antibody was 
incubated with increasing  concentrations of protein C. The 
data were fit  as described under  “Experimental  Procedures” 
and  are  represented  in  the  form f a semi-log plot. The  results 
of the fitting process indicate a KO of 1.4 nM. In order to 
compare the relative affinity of the  antibody for protein C 
with  that of prothrombin, a competitive experiment was con- 
ducted  in which 7D7B10 was incubated  with  protein C im- 
mobilized on microtiter wells in  the presence of increasing 
concentrations of selected proteins (Fig. 3). These studies 
indicate that  the relative affinity of 7D7B10 for protein C is 
approximately 30-40-fold higher than its affinity for pro- 
thrombin.  In  contrast,  factor  IX  and bovine protein C were 
unable  to compete in  this assay.  Additional experiments  dem- 
onstrated that prothrombin fragment 1 and factor X were 
also  able to  inhibit  the  binding of protein C to 7D7B10 with 
50% inhibition occurring in the 1-3 p M  range (data not 
shown).  Furthermore, decarboxylated prothrombin,  in which 
the Gla residues had been quantitatively converted to glu- 
c3 
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FIG. 2. Sandwich ELISA of protein C binding  to  monoclonal 
antibody 7D7B10. Antibody (20,lO or 5 pg/ml) was incubated  with 
increasing concentrations of protein C (as indicated) in  TBS, 0.1% 
BSA, 30 mM EDTA at 25 “C. After 20 min, 100-pl aliquots were 
added to microtiter wells that had been precoated with specific rabbit 
anti-protein C  antisera. The protein C-7D7B10 complex was detected 
by incubation with peroxidase-conjugated anti-mouse immunoglobu- 
lin (from  goat) as described under  “Experimental  Procedures.” 
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FIG. 3. Competitive binding assay measuring the interac- 
tion  of  protein C and structurally homologous proteins with 
monoclonal  antibody 7D7B10. Microtiter wells were coated  with 
1 pg  of protein C. An aliquot (100 pl) of dilutions of human protein 
C (O), human prothrombin (A), human factor IX (O), or bovine 
protein  C (.) was preincubated  with 100 pl (0.5 pg/ml) of 7D7B10 
for 1 h  prior to addition to  the microtiter  plate. Following incubation 
and washing, bound antibody was detected by using a rabbit anti- 
mouse IgG-alkaline  phosphatase conjugate. 
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FIG. 4. Effect of varying CaClz concentration on  protein C 
binding  to  antibody. 7D7B10 (5.2 pg/ml) and protein C (2.0 pg/ 
ml) were incubated  with  increasing concentrations of  CaC12 as indi- 
cated in  TBS, 0.1% BSA at 25 “C for 25 min. Aliquots (100 pl) were 
assayed for protein C-7D7B10 complex as described in  the legend to 
Fig. 2. 
tamic acid, competed equally well (KO.5 = 3.6 p ~ )  as control 
prothrombin (KO.5 = 4.3 p ~ )  (data  not  shown).  Similar  exper- 
iments  demonstrated  that  protein S was  unable to compete 
for  binding  (data  not  shown). 
Effect of Metal Ions on  Protein C Binding to 7D7BlO”Fig. 
4 shows the dependence of protein C-7D7B10 complex for- 
mation  on  the  concentration of Ca2+. Interestingly, low con- 
centrations of Ca2+  enhanced  protein C binding  to 7D7B10 
with a of 55 p ~ ,  whereas higher concentrations inhibited 
the  interaction 1.1 mM). The  addition of EDTA  in 
excess of added Ca2+  caused  complete  reversal of the  inhibi- 
tion  with  the  appearance of the  same signal as  obtained  in 
the absence of added  metal ion. Fig. 5 compares  the  ability of 
various divalent  metal  ions (chloride salts)  to  inhibit  binding 
for protein C to  bind  to  the  antibody  since  binding occurred 
at concentrations of various metal ions from 0.04 mM to 
approximately 1.0 mM. However, higher concentrations of 
divalent  metal ions inhibited  the  interaction. Ca2+ and  Mn2+ 
behaved similarly, having KO.5 values of 1-2 mM, whereas 
higher concentrations of Ba2+ or M$+ were required with K0.5 
values of 5 and 20 mM, respectively. In all  cases, saturating 
levels of metals  resulted  in complete inhibition of protein C 
binding  to  the  antibody.  In  control  experiments  using radio- 
labeled protein C ,  it  was found  that  the  capture  step of the 
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FIG. 5. Effect of increasing concentrations of various di- 
valent metal ions on protein C binding to antibody. Protein C 
(2.0 pg/ml)  and 7D7B10  (5.2  pg/ml) were incubated  with  increasing 
concentrations of each  metal ion (as  indicated) in TBS, 0.1% BSA a t  
25 "C for 25 min. Protein C-7D7B10  complex was measured as 
described in the legend to Fig. 2. EDTA (O), Caz+ (O), Mg"' (A), 
Mn2+ (A), and  BaZ+ (0). 
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FIG. 6. SDS-PAGE and immunoblot of prothrombin and its 
proteolytic fragments. All samples were reduced with  0-mercap- 
toethanol. Lanes 1 and 8, protein standards; lunes 2 and 10, early 
digest of prothrombin  with  a-chymotrypsin (1 min); lanes 3 and 11, 
late digest of prothrombin  with  a-chymotrypsin (120 min); lunes 4 
and 12, prothrombin digest with a-thrombin; lanes 5 and 13, a- 
thrombin; lanes 6 and 14, fragment 1 (partially degraded); lane 9, 
prestained  protein  standards. Lanes 1-9 were stained with  Coomassie 
Blue R-250. Lanes 10-15 were blotted to nitrocellulose and probed 
with monoclonal antibody 7D7B10 followed by anti-mouse Ig, "'7- 
labeled F(ab')*  (from  sheep). 
ELISA was not affected  by these  concentrations of the  various 
metal ions. 
Location of the  Epitope  Region for Monoclonal 7D7BlO- 
Western  blotting  experiments revealed that 7D7B10 binds  to 
the protein C light chain (data not shown), demonstrating 
that this antibody binds to the amino-terminal portion of 
protein C. Fig. 6  shows the  results of SDS-PAGE  analysis of 
prothrombin and its proteolytic fragments as detected by 
Coomassie Blue staining  or  after  immunoblotting.  The  epi- 
tope was detected  in  intact  prothrombin 1-579 (lane 10)  as 
well as in fragment 1, 1-155 (lanes 12 and 14) but not in 
prethrombin 1, 156-579 (50,000-Da position in lune 12) or 
thrombin 272-579 (lane 13).  The  reactivity to  only a  single 
fragment of the  parent molecule is  consistent  with  the mono- 
clonal  nature of the  antibody.  The  epitope was further local- 
ized to  the  NH2-terminal region of prothrombin by indirect 
evidence since  chymotryptic cleavage of the Gla  domain 1-44 
resulted  in loss of the  epitope (lune 11 ). Likewise, degradation 
products of fragment  1, which arose upon prolonged storage 
a t  4 "C, were not  detected by immunoblotting (lane 14).  The 
degraded form  having M ,  of 22,000 is presumably fragment  1, 
51-155 as  has been reported by others  (Aronson et al., 1980). 
Direct visualization of monoclonal antibody  binding  to  the 
Gla domain 1-44 was not obtained, presumably due to the 
inefficiency of nitrocellulose in capturing smaller peptides. 
Further  studies revealed that  chymotrypsin  treatment of pro- 
tein C, which  removed the  Gla  domain, also  resulted in a loss 
of the  epitope  upon  Western  blotting  (data  not  shown), which 
is  consistent  with  the  immunoblotting  data  with  prothrombin 
and suggests that  the  epitope  is located within  the Gla regions 
of both  protein C and  prothrombin. 
To  confirm  whether 7D7B10 binds  to  an epitope  expressed 
within the Gla domain, synthetic peptides were employed. 
The synthetic peptides corresponding to residues 1-22  of 
human protein C and 1-12 and 13-29 of human factor VI1 
were generously  supplied by Dr. William Church of the  Uni- 
versity of Vermont  (Burlington).  These  peptides were coated 
to  the wells of microtiter  plates  and  increasing  concentrations 
of antibody  added  to  each well. The  results of this  study (Fig. 
7) revealed that 7D7B10 bound  to  the  peptide  representing 
protein C, 1-22, but  not  to  peptides  representing factor VII, 
1-12, or factor VII, 13-29. A  more  precise understanding of 
residues important for binding of the  antibody  to  this  portion 
of protein C  was  explored  by preparing various peptides from 
this region. For  these  studies, a competitive binding assay was 
performed measuring  the  ability of the  synthetic  peptide  to 
compete  with  protein C for  binding  to 7D7B10. The  results 
are  summarized  in  Table I11 and  demonstrate  that a peptide 
representing  human  protein C, 1-15, was able to compete  for 
binding, whereas no  binding of the  peptides corresponding to 
human  protein C, 1-7, protein C, 9-16, or protein C, 10-22, 
was  detectable. 
The  observation  that 7D7B10 did not  bind  to b vine protein 
C  was pursued by examining  the relative binding of peptides 
corresponding  to  human  protein C, 1-15, uersus bovine pro- 
tein C, 1-15, by competitive sandwich ELISA. The results, 
shown  in Fig. 8,  indicated  that  although  both  peptides were 
able  to  compete  with  protein C for  binding to  the  antibody, 
the  human  protein C peptide  representing residues 1-15 had 
approximately a 100-fold higher  affinity than  the  correspond- 
ing  peptide  based  upon  the bovine  sequence,  which  differed 
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Binding of 7D7B10 to immobilized synthetic pep- 
tides. Peptides were coated  to  the wells of microtiter  plates (Immulon 
11) by incubation  overnight in 0.1 M sodium carbonate buffer, pH 9.5. 
The wells were then blocked with TBS, 0.1% BSA and incubated 
with varying  concentrations of 7D7B10 in  TBS, 0.1% BSA. Bound 
antibody was detected as described for the sandwich assay. The 
peptides used corresponded to human protein C, 1-22 (O), human 
factor VII, 1-12 (O), and  human  factor VII, 13-29 (A). 
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TABLE 111 
Relative  competitiveness of various  peptides in displacing protein C from antibody  complex 
Equimolar concentrations of antibody 7D7B10 and protein C (32 nM) were incubated in the presence of 
increasing concentrations of various peptides. The amount of protein C-7D7B10 complex  was measured by sandwich 
ELISA as described under "Experimental Procedures." hPC,  human  protein C; bPC, bovine protein C. 
Peptide 
Sequence 
1" 5 10 15 20 KO.6 
P M  
hPC, 1-15 
bPC, 1-15 
hPC, 7-15 
hPC, 9-16 
hPC, 10-22 
A N S F L E E L R H S S L E R  
A N S F L E E L R P G N V E R  
E L R H S S L E R  
3.3 
200 
1500 
>990 
>650 
A N S F L E E  >2000 
R H S S L E R E  
R H S S L E R E C I E E I C  
hPC, 1-7 
Residue number. 
0 .. . 1 
X 
I 
x Y)" 
a 
t 
[PEP T I D E ]  pM 
FIG. 8. Comparison of the binding of synthetic peptides cor- 
responding to human protein C, 1-15, and bovine protein C, 
1-15, to  antibody 7D7B10. Protein C (2.0 pg/ml) and 7D7B10 
(5.2 pg/ml) were incubated with increasing concentrations of peptides 
corresponding to human protein C, 1-15 (A), or bovine protein C, 1- 
15 (O), in TBS, 0.1% BSA for 25 min at 25 "C. The protein C- 
antibody complex  was captured and  quantitated  as described in the 
legend to Fig. 2. 
only in the 4 residues at  positions 10-13. 
Effect of Monoclonal Antibody on Protein C/APC Func- 
tion-Preincubation of protein  C with excess 7D7B10 anti- 
body in the presence of EDTA  had no effect on  protein  C 
activation by PCA. These experiments were done at low 
concentrations of protein  C such that  an effect on the K,,, as 
well as  the V of the reaction would  be observed. Likewise, the 
antibody had no effect on APC amidolysis of the chromogenic 
substrate S-2266. We also examined the effect of 7D7B10 on 
APC inactivation of immunoaffinity-purified factor VIII, as 
measured by its cofactor activity  in a purified factor X acti- 
vation assay. Preliminary experiments established a time- 
dependent decrease in  factor VIII cofactor activity which was 
dependent upon APC in  a dose-dependent manner (not 
shown). Relatively high concentrations of APC  were required 
(46 nM) because the inactivation reaction was carried out in 
the absence of millimolar concentrations of Ca2+ and phos- 
pholipid, which accelerate APC inactivation of factor VIII. 
This was necessary since these  concentrations of Ca2+  inhibit 
antibody binding to protein C. Under these conditions in 
which APC was incubated with factor VI11 in  the presence of 
micromolar concentrations of CaClZ but in the absence of 
phospholipid cofactor, 7D7B10 had no effect on the inacti- 
vation of factor VI11  by  APC. 
DISCUSSION 
In  the process of preparing monoclonal antibodies  to human 
protein C, antibodies were found which required the presence 
of Caz+ to bind to protein C, as  has been reported by others. 
In addition, a different type of antibody was observed in 
which the binding of the antibody to protein  C was inhibited 
by Ca2+ in  the millimolar concentration range. In  the screen- 
ing assay, these antibodies bound to protein C only when 
EDTA was added in excess to  the 2 mM Ca2+  present as a 
constituent of the hybridoma culture media. The frequency 
of such clones, loosely referred to as EDTA-dependent clones, 
was  2.5-fold higher than  that of the Caz+-dependent clones. 
One EDTA-dependent monoclonal antibody, 7D7B10, has 
been purified and its properties characterized further. The 
protein specificity of 7D7B10  was not absolute for protein C. 
Thus,  in solid-phase screening assays as well as in immuno- 
blotting  experiments using highly purified human  proteins, 
the antibody was found to react  with  prothrombin and factor 
X, in  addition to protein C. In  contrast, no binding to factor 
IX,  protein S, or  to bovine protein  C was observed. The lack 
of specificity was also observed in immunoaffinity experi- 
ments  in which significant amounts of prothrombin copurified 
with protein C using 7D7BlO-Sepharose chromatography. 
Quantitative information regarding the relative affinity of 
7D7B10 for the various proteins in solution was obtained 
using a sandwich ELISA. These results indicated that  the 
affinity of the antibody for prothrombin,  fragment 1 of pro- 
thrombin, or factor X is approximately 30-40-fold weaker 
than  its affinity for protein C. 
The location of the epitope of 7D7B10  was delineated by 
immunoblotting  using proteolytic fragments and by the use 
of synthetic peptides. Antibody binding to fragment 1 of 
prothrombin as well as  to  the light chain of protein  C was 
observed on immunoblots, indicating that the epitope was 
located in  the  NHz-terminal 155 residues of either protein. 
Antibody binding to  other fragments covering the  entire co- 
valent structure of these proteins was not observed. In addi- 
tional  experiments,  chymotryptic leavage of either protein  C 
or prothrombin, which results in removal of the NHn-terminal 
approximately 40-residue Gla domain, resulted in loss of the 
epitope. This provided evidence, albeit  indirect, further local- 
izing antibody binding to  the Gla domain. The use  of synthetic 
peptides confirmed that  this monoclonal antibody binds to 
the Gla domain of protein C. Thus, synthetic  peptides repre- 
senting  protein C,  1-22, and protein C,  1-15,  were capable of 
binding to  the monoclonal antibody.  A peptide representing 
protein C, 7-15, bound weakly to  the antibody, whereas pep- 
tides  representing  protein  C, 1-7, protein C,  9-16, and protein 
C, 10-22, did not  bind  under the conditions examined. Fur- 
thermore, peptides representing  factor VII, 1-12, and factor 
Conformational  Changes and Domain  Interactions in Protein C 18787 
VII, 13-29, did not  bind to  this antibody. In agreement with 
results comparing the ability of human  and bovine protein c 
to bind to  this monoclonal it was found that a peptide repre- 
senting bovine protein C, 1-15 had a much lower affinity for 
the antibody than  its  human  counterpart.  The results of all 
of these  studies  indicate that  the  first  15 residues of protein 
C  represent the major binding region for this antibody and 
that residues 10-13 appear particularly important for the 
interaction. Although residues 10-13 appear necessary for 
maximal binding, they  are not sufficient since peptide human 
protein C, 7-15, encompassing this region bound relatively 
poorly. 
During the course of this investigation,  Church et al. (1988) 
identified a monoclonal antibody (H-11)  to human  protein C, 
the binding of which was also inhibited by divalent  metal  ions 
and which lacked specificity for protein C. These studies 
demonstrated that  the epitope was located in the Gla domain, 
and  that residues 4-9 (Phe-Leu-Glu-Glu-Leu-Arg) were im- 
portant components of the epitope. Despite the similarities 
between these two antibodies, several features distinguish 
their interaction with protein C. Although both antibodies 
cross-reacted with other vitamin  K-dependent  proteins, the 
protein specificities differed. Thus, H-11 bound to bovine 
protein  C, whereas 7D7B10 did not interact with the bovine 
molecule. A second difference observed between these two 
antibodies was the degree of metal ion inhibition of the 
interactions. Although saturating levels of divalent  metal  ions 
caused complete inhibition of 7D7B10 binding to protein C, 
these same metals resulted in only partial inhibition of H-11 
binding. Also, the dependence of the inhibition on M P  
concentration was quite different in the two systems, with 
significantly higher concentrations required in the case of 
7D7B10 for inhibition of binding. Finally, these two antibod- 
ies displayed a  distinct peptide specificity since H-11 bound 
to factor VII, 1-12, whereas 7D7B10 did not. These data 
taken together confirm that these two antibodies interact  in 
a different manner with protein C. 
No effect of antibody 7D7B10 on various aspects of protein 
C or APC function was found. The antibody did not affect 
the initial rate of protein C activation by PCA, a specific 
activating enzyme from snake venom (Kisiel et al., 1987a, 
1987b; Orthner et al., 1988). Nor did 7D7B10 have an effect 
on the activity of APC as measured using a  small  synthetic 
substrate. Likewise, no effect of antibody was observed on  the 
inactivation of purified factor VI11 by APC in the absence of 
Ca2+ and phospholipid cofactors. Thus, under these condi- 
tions,  no evidence was found for an effect of antibody binding 
to APC on its interaction with factor VIII. The effect of the 
antibody on this reaction in the presence of Ca2+ and phos- 
pholipid cofactors could not be determined since these  con- 
centrations of Ca2+ inhibit 7D7B10 binding to APC. In sum- 
mary, antibody to protein C or APC, shown to occur in  the 
Gla domain of the light chain, was found to have no effect on 
events occurring in the heavy chain such as limited proteolytic 
cleavage to APC or active site-catalyzed hydrolysis of chro- 
mogenic or macromolecular substrates. Since the tertiary 
structure of protein  C is not known, this would suggest that 
the Gla region is sufficiently distant in space from the  acti- 
vation and catalytic site regions such that steric effects by the 
antibody molecule  were not observed. 
The concentration of Ca2+ required to inhibit antibody 
binding to protein  C  correlates  quite well with published data 
examining the binding of this metal to  the molecule. Thus, 
equilibrium binding data have shown that bovine protein  C 
contains 16 equivalent sites for ca2+ with a KO of 0.9 mM 
(Amphlett et al., 1981). In addition to Ca2+, protein C also 
binds  Mn2+ and M P ,  and binding studies  with  Mn2+ have 
demonstrated multiple binding  sites for this metal  in the Gla 
domain of bovine protein  C with an average KO of 0.2 mM 
(Hill and Castellino, 1987). Competition experiments have 
shown that high concentrations of M e  were able to displace 
Ca2+ from these sites  (Amphlett et al., 1981). One interpreta- 
tion of the present data is that  the binding of Ca2+, Mn2+,  or 
Mg2+ to  the Gla domain inhibits interaction of the antibody 
by decreasing the accessibility of the epitope resulting  from  a 
conformational change. Interestingly,  results of x-ray  crystal- 
lographic determination of the  three dimensional structure of 
fragment 1 of prothrombin demonstrated that  the first 35 
residues of this molecule  were disordered (Park  and Tulinsky, 
1986). Furthermore, more recent  x-ray crystallographic data 
indicated that  this region of fragment 1 became ordered in 
the presence of Ca2+. An alternative  explanation is that Ca2+ 
directly interferes  with  antibody binding by occupying ligand 
groups of protein  C required for interaction with the antibody. 
However, this seems unlikely since Gla residues, which are 
necessary for Ca2+  binding to  this domain, did not appear to 
be involved in antibody binding. This was seen  in  experiments 
with prothrombin in which conversion of the Gla residues to 
glutamic acid residues had no effect on the interaction of this 
molecule with the antibody. It was also seen in the binding 
studies using peptides that contained glutamic acid residues 
in place of Gla. 
In addition to  the sites discussed above, protein  C has been 
shown to contain a single high affinity site for Ca2+ (KO, 
approximately 100 p ~ )  exclusive of the Gla domain (Esmon 
et al., 1983; Johnson et al., 1983), which is located in the  EGF 
homology domain of the light chain (Ohlin et al., 1988). 
Interestingly, in the present study, it was found that low 
concentrations of Ca2+  enhanced monoclonal binding to pro- 
tein C with a of 55 p ~ .  The possibility that this effect 
resulted from two populations of antibodies, one of which 
bound to  the EGF-like domain but could not be detected by 
blotting, was considered. However, the results of cell-sorting 
analysis of the 7D7B10 hybridoma cells gave no indication 
for heterogeneity. Therefore, it is likely that Ca2+ occupation 
of this  site causes a  conformational change that enhances the 
binding of the 7D7B10 antibody to  the Gla domain of protein 
C. Other studies have found that occupation of the high 
affinity  metal-binding site results in  alterations detected  in 
both  the catalytic region (Steiner et al., 1980) as well as  the 
activation cleavage site (Esmon et al., 1983; Johnson et al., 
1983; Kisiel et al., 1987a; Orthner et al., 1988, Stearns et al., 
1988). The results from the present study provide the first 
evidence suggesting that metal binding to  the  site in the  EGF 
homology region results in a conformational change in the 
Gla region and  that these two domains interact in the protein 
C molecule. 
It is interesting to speculate on the possible role of the 
epitope recognized by the 7D7B10 antibody, which is con- 
served among several of the vitamin  K-dependent  proteins. 
The epitope is located in a region of the molecule thought to 
be highly disordered based upon the three-dimensional struc- 
ture analysis of homologous prothrombin  fragment 1. It seems 
unlikely, therefore, that  the epitope is part of a structural 
motif involved in folding of the protein. On the  other hand, 
although the epitope is probably not part of a  Ca2+-binding 
site per  se, it may be necessary for an appropriate conforma- 
tional response that occurs upon Ca2+ binding to the Gla 
domain. Another possibility is that  this region of the molecule 
may  be important in post-translational processing events.  For 
example, it may  be part of a binding site for the vitamin K- 
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dependent carboxylase. These possibilities will be interesting 
subjects for future studies. 
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